While immune checkpoint blockades (ICBs), particularly anti‐PD‐1/PD‐L1 antibodies, have emerged as the most promising antitumor therapy, the response rate in NSCLC patients remains relatively low, hovering around 20%.2 The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.